Protagonist Therapeutics, Inc.

PTGX · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.7%

Institutions120.2%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	–	–	–	–	–	$30.93M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$158.13M	$252.84M	-$93.65M	-$131.37M	-$125.84M	-$64.52M	-$80.52M	-$42.27M	-$37.90M	-$32.67M
Operating income as a percentage of revenue.	–	–	–	–	–	–	–	-136.7%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$130.15M	$275.19M	-$78.95M	-$127.39M	-$125.55M	-$66.15M	-$77.19M	-$38.92M	-$36.96M	-$37.18M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.05	$4.47	$-1.39	$-2.60	$-2.71	$-1.92	$-2.98	$-1.74	$-2.00	$-5.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.05	$4.23	$-1.39	$-2.60	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$128.39M	$97.25M	$186.73M	$125.74M	$123.67M	$117.36M	$33.01M	$82.23M	$106.03M	$21.08M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$668.19M	$744.73M	$357.95M	$247.93M	$347.69M	–	$154.92M	$139.47M	$163.73M	$93.99M
Everything the company owes — debt, unpaid bills, and other obligations.	$53.48M	$69.43M	$21.27M	$32.32M	$47.67M	–	$74.95M	$26.96M	$43.10M	$6.43M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$614.71M	$675.29M	$336.68M	$215.61M	$300.02M	–	$79.96M	$112.52M	$120.63M	$87.56M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$57.67M	$184.15M	-$70.24M	-$108.14M	-$107.86M	-$72.48M	-$41.53M	-$49.95M	$3.87M	-$29.97M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.59M	$1.35M	$609000	$795000	$1.10M	$471000	$967000	$486000	$666000	$379000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$56.08M	$182.80M	-$70.84M	-$108.93M	-$108.97M	-$72.95M	-$42.49M	-$50.43M	$3.21M	-$30.35M

	You	Peer avg
P/E	141.5	–
Revenue Growth	+3749.2%	+122.9%
ROE	11.0%	-56.2%

Protagonist Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison